Board of Directors

Charles Large

Chairman of the Board

Charles Large, PhD, is CEO and Founder of Autifony Therapeutics, a clinical stage company based in the UK.  Previously he was Director of Molecular and Cellular Biology within the Neuroscience Centre of Excellence for Drug Discovery at GlaxoSmithKline. Dr Large has over 30 years of experience in drug discovery and is an expert on drugs that modulate voltage-gated ion channels.

Greg Jones

Board Member

Greg serves as VP of Legal Affairs at Novo Nordisk specializing in licensing, mergers & acquisitions.  Prior to Novo Nordisk, he served as assistant general counsel for Medco and played a key role in the $29B acquisition by Express Scripts.  A previous associate at renowned law firm Davis Polk, Mr. Jones earned a bachelor’s in political science from Wake Forest University and a law degree from Vanderbilt Law School.

Søren Lemonius

Board Observer

Søren Lemonius is Managing General Partner and one of the three co-founders of Sunstone. Søren has particular focus on Investor relations and therapeutics. Søren has 20 years’ experience from corporate management in R&D-intensive companies. As Innovation Manager at FOSS Analytical (a food diagnostics company), Søren successfully implemented new analytical technologies. Prior to joining Sunstone, Søren served as Chief Technology Officer at Danionics (an electronic component company) where he participated in developing the company from a private, 30-employee, venture-backed technology company to a EUR +27 million revenue, +300-employee, listed company. Søren holds a master’s degree in Experimental Cell Biology from the University of Southern Denmark.

Simon Mølgaard

Co-founder and Chief Executive Officer

Simon Molgaard, PhD, is co-inventor of key Teitur patents. Author of key neuroscience publications over the last 10 years. Has led research, operations, financing and initiation of key collaborations for this project since 2015. Former visiting scientist at Mayo Clinic, US.

Anders Dalby

Co-founder and Chief Scientific Officer

Anders, MSc in Molecular Medicine, has headed research and laboratory work for Teitur and is co-inventor of key Teitur patents. Has established core assays for optimizing Teitur therapeutic peptides and establishing mechanism of action. His research fields include molecular neuroscience, cell biochemistry, molecular imaging and structural-activity relationships of peptides.

Mathias Kaas Ollendorff

Co-founder and Head of in vivo Pharmacology

Mathias Kaas Ollendorff, MD, has 10+ years experience in neuroscience with particular focus on behavioural phenotyping of sortilin receptor transgenic models. He has guided the testing of Teitur peptides in animal models of neurodegeneration and the assessment of pharmacokinetic properties.